Premium
Serum biomarkers of fibrostenotic Crohn's disease: Where are we now?
Author(s) -
He Jin Shen,
Tan Jin Yu,
Li Xiao Zhi,
Feng Rui,
Xiong Shan Shan,
Lin Si Nan,
Qiu Yun,
Mao Ren
Publication year - 2020
Publication title -
journal of digestive diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 51
eISSN - 1751-2980
pISSN - 1751-2972
DOI - 10.1111/1751-2980.12913
Subject(s) - medicine , fibrosis , disease , extracellular matrix , inflammatory bowel disease , biomarker , crohn's disease , gastroenterology , bioinformatics , biochemistry , chemistry , biology , microbiology and biotechnology
Intestinal fibrosis and subsequent stricture formation are major clinical challenges in inflammatory bowel disease, resulting in an increased rate of operation and poor prognosis compared with those without. With the changing perception that intestinal fibrosis is irreversible to the point of view that it is reversible in recent years, various candidate serum biomarkers have been studied over the past decades, which may stratify patients based on their risks of developing stenosis and enable the detection of early stages of fibrosis. However, reliable and accurate biomarkers are still unavailable due to conflicting results and the lack of high‐quality evidence. In this review we summarized the serum biomarkers that have been proposed for intestinal fibrosis in recent years, which includes gene polymorphisms or variants, epigenetic markers, extracellular matrix components, growth factors, and antibodies, aiming to provide clues for future research.